{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T21:37:03Z","timestamp":1770068223854,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.modpat.2023.100166","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T11:26:45Z","timestamp":1679916405000},"page":"100166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3791-3204","authenticated-orcid":false,"given":"Fatima Zahra","family":"Jelloul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres E.","family":"Quesada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard K.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Cameron","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siba","family":"El Hussein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland L.","family":"Bassett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabet E.","family":"Manasanch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muzaffar H.","family":"Qazilbash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keyur P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.modpat.2023.100166_bib1","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/blood-2018-08-825349","article-title":"Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing","volume":"133","author":"Kumar","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.modpat.2023.100166_bib2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.leukres.2018.07.016","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma","volume":"74","author":"Radivoyevitch","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.modpat.2023.100166_bib3","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1038\/s41467-020-16805-5","article-title":"Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant","volume":"11","author":"Mouhieddine","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.modpat.2023.100166_bib4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","article-title":"Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data","volume":"15","author":"Palumbo","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.modpat.2023.100166_bib5","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.modpat.2023.100166_bib6","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.modpat.2023.100166_bib7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41408-021-00454-y","article-title":"Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma","volume":"11","author":"Nadiminti","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.modpat.2023.100166_bib8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jmoldx.2018.08.002","article-title":"Ultra-rapid reporting of GENomic targets (URGENTseq): clinical next-generation sequencing results within 48 hours of sample collection","volume":"21","author":"Patel","year":"2019","journal-title":"J\u00a0Mol Diagn"},{"issue":"1","key":"10.1016\/j.modpat.2023.100166_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2020.101144","article-title":"Second malignancies in multiple myeloma; emerging patterns and future directions","volume":"33","author":"Maclachlan","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"issue":"10","key":"10.1016\/j.modpat.2023.100166_bib10","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3324\/haematol.2015.127548","article-title":"Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years","volume":"100","author":"Engelhardt","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.modpat.2023.100166_bib11","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1038\/bcj.2013.19","article-title":"Patterns\u00a0of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics","volume":"3","author":"Razavi","year":"2013","journal-title":"Blood Canc J"},{"issue":"15","key":"10.1016\/j.modpat.2023.100166_bib12","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2011-05-355743","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)","volume":"118","author":"Mailankody","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.modpat.2023.100166_bib13","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1054\/bjoc.2001.1998","article-title":"Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958\u20131996: a search for common mechanisms","volume":"85","author":"Dong","year":"2001","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.modpat.2023.100166_bib14","first-page":"4507","article-title":"Increased incidence of a second lymphoproliferative malignancy in patients with multiple myeloma\u2013a SEER based study","volume":"32","author":"Chakraborty","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.modpat.2023.100166_bib15","article-title":"Risk of second primary cancers in multiple myeloma survivors in German and Swedish cancer registries","volume":"6","author":"Chen","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.modpat.2023.100166_bib16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clml.2014.07.001","article-title":"Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia","volume":"15","author":"Pemmaraju","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.modpat.2023.100166_bib17","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3109\/10428194.2014.970543","article-title":"Therapy-related myelodysplastic syndrome\/acute leukemia after multiple myeloma in the era of novel agents","volume":"56","author":"Gertz","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.modpat.2023.100166_bib18","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1365-2141.1996.d01-1891.x","article-title":"Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma","volume":"95","author":"Govindarajan","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.modpat.2023.100166_bib19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-020-00400-4","article-title":"Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients","volume":"11","author":"Rosenberg","year":"2021","journal-title":"Blood Cancer J"},{"issue":"29","key":"10.1016\/j.modpat.2023.100166_bib20","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.modpat.2023.100166_bib21","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.modpat.2023.100166_bib22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.modpat.2023.100166_bib23","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/leu.2013.34","article-title":"Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients","volume":"27","author":"Roeker","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.modpat.2023.100166_bib24","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/jmedgenet-2011-100674","article-title":"Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms","volume":"49","author":"Schulz","year":"2012","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.modpat.2023.100166_bib25","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.modpat.2023.100166_bib26","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.modpat.2023.100166_bib27","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","article-title":"Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma","volume":"35","author":"Gibson","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.modpat.2023.100166_bib28","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1182\/blood-2009-10-249128","article-title":"Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia","volume":"115","author":"Litzow","year":"2010","journal-title":"Blood"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395223000716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395223000716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:24:57Z","timestamp":1760232297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395223000716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0893395223000716"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2023.100166","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2023.100166","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 United States & Canadian Academy of Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100166"}}